Cover Image
Market Research Report

Global Celiac Disease Drugs Market 2017-2021

Published by TechNavio (Infiniti Research Ltd.) Product code 522237
Published Content info 76 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Celiac Disease Drugs Market 2017-2021
Published: June 28, 2017 Content info: 76 Pages
Description

About Celiac Disease Drugs

Celiac disease is an autoimmune inflammatory disease of the small intestine, which is triggered by intake of gluten from wheat and other sources through our food. Presently, there is no specific drug approved for celiac disease, and the first line of treatment is completely dominated by a gluten-free diet. There are few anti-inflammatory and immunosuppressant drugs and nutritional supplements that are used as off-label therapy in celiac disease. All these off-label therapies are considered as second-line of treatment.

Technavio's analysts forecast the global celiac disease drugs market to grow at a CAGR of 24.22% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global celiac disease drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Celiac Disease Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Pfizer

Other Prominent Vendors

  • ADMA Biologics
  • Amgen
  • Anthera Pharmaceuticals
  • Bayer
  • Biogen
  • BioLineRx
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • Celimmune
  • ImmunogenX
  • Immunomedics
  • ImmusanT
  • Innovate Biopharmaceuticals
  • Kedrion Biopharma
  • LFB Group
  • Novartis
  • Shire
  • Takeda Pharmaceutical

Market driver

  • Prevalence of disease
  • For a full, detailed list, view our report

Market challenge

  • Long-term sustainability
  • For a full, detailed list, view our report

Market trend

  • Inorganic growth strategies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR13380

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of celiac disease

PART 06: Market landscape

  • Market overview
  • Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by therapy type

  • First line of treatment
  • Second line of treatment

PART 09: Geographical segmentation

  • Celiac disease drugs market in Americas
  • Celiac disease drugs market in EMEA
  • Celiac disease drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Inorganic growth strategies
  • Robust pipeline

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Stage 1: Initiation process in celiac disease
  • Exhibit 02: Stage 2: Triggering phase in celiac disease
  • Exhibit 03: Diagnostic approach for celiac disease
  • Exhibit 04: Global celiac disease drugs market snapshot
  • Exhibit 05: Global celiac disease drugs market 2016-2021 ($ millions)
  • Exhibit 06: Opportunity analysis in global celiac disease treatment market
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Pipeline analysis of key molecules for celiac disease
  • Exhibit 09: Key clinical trials: Celiac disease drugs 2016
  • Exhibit 10: Segmentation of global celiac disease drugs market by therapy type 2016
  • Exhibit 11: Global celiac disease first line of treatment market 2016-2021 ($ millions)
  • Exhibit 12: Various drug classes used in second line of treatment of celiac disease
  • Exhibit 13: Global celiac disease second line of treatment market 2016-2021 ($ millions)
  • Exhibit 14: Segmentation of global celiac disease drugs market by geography 2016 and 2021
  • Exhibit 15: Segmentation of global celiac disease drugs market revenue by geography 2016-2021 ($ millions)
  • Exhibit 16: Market scenario in Americas
  • Exhibit 17: Celiac disease drugs market in Americas 2016-2021 ($ millions)
  • Exhibit 18: Market scenario in EMEA
  • Exhibit 19: Celiac disease drugs market in EMEA 2016-2021 ($ millions)
  • Exhibit 20: Market Scenario in APAC
  • Exhibit 21: Celiac disease drugs market in APAC 2016-2021 ($ millions)
  • Exhibit 22: Widely consumed foods containing gluten
  • Exhibit 23: The consumption rate of beer in US 2011-2015
  • Exhibit 24: Government initiatives by various countries for celiac disease
  • Exhibit 25: Various symptoms associated with celiac disease
  • Exhibit 26: Factors affecting long-term sustainability of gluten-free diet
  • Exhibit 27: Inorganic growth strategies for global celiac disease drugs market
  • Exhibit 28: Competitive structure analysis of global celiac disease drugs market 2016
  • Exhibit 29: Competitive factors of global celiac disease drugs market
  • Exhibit 30: Market penetration of various celiac disease drugs manufacturers worldwide 2016
  • Exhibit 31: Strategic success factors of companies in global celiac disease drugs market
  • Exhibit 32: F. Hoffmann-La Roche: Key highlights
  • Exhibit 33: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 34: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 35: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 36: Johnson & Johnson: Key highlights
  • Exhibit 37: Johnson & Johnson: Strength assessment
  • Exhibit 38: Johnson & Johnson: Strategy assessment
  • Exhibit 39: Johnson & Johnson: Opportunity assessment
  • Exhibit 40: Merck: Key highlights
  • Exhibit 41: Merck: Strength assessment
  • Exhibit 42: Merck Strategy assessment
  • Exhibit 43: Merck: Opportunity assessment
  • Exhibit 44: Pfizer: Key highlights
  • Exhibit 45: Pfizer: Strength assessment
  • Exhibit 46: Pfizer: Strategy assessment
  • Exhibit 47: Pfizer: Opportunity assessment
Back to Top